secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvalent, Inc. (NUVL)
CIK:        0001861560
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0000950170-25-104531
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvalent Q2 2025 net loss $99.7M; rolling NDA for zidesamtinib initiated
------------------------------------------------------------------------

- Net loss $99.7M; R&D $80.9M, G&A $23.7M; cash $1.0B funding into 2028.
- Rolling NDA for zidesamtinib (ROS1+ NSCLC) initiated; target completion Q3 2025; FDA RTOR pilot.
- ALKAZAR Phase 3 of neladalkib (ALK+ NSCLC) dosed; topline TKI pre-treated data expected year-end 2025.
- Preliminary data for neladalkib in ALK+ solid tumors at ESMO 2025 (Oct 17-21).
- Jason Waters promoted to SVP Commercial; Christy Oliger appointed to board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1861560/000095017025104531/0000950170-25-104531-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1861560/000095017025104531/nuvl-20250807.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-104531

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer